Purpose: To examine ovarian reserve following chemotherapy in women with Hodgkin's disease.
Methods: The study included nine patients who underwent ovarian tissue cryopreservation (OTCP) prior to chemotherapy consisting of the ABVD regimen (Adriamycin, bleomycin, vinblastine, and dacarbazine) and co-treatment with gonadotropin-releasing hormone agonist (GnRH-a) (Group A), and 13 patients treated by the ABVD protocol only without GnRH-a (Group B). The average age was 25.2 +/- 2.7 years for the women in Group A and 31.8 +/- 6.8 years for those in Group B.
Results: Six months following the end of chemotherapy, the menstrual cycle resumed in all Group A patients and in four Group B patients who had amenorrhea. Eight Group B patients had regular menses during and after chemotherapy. None of the patients suffered from ovarian failure. Two Group A patients conceived in the first year after completing chemotherapy.
Conclusions: Co-treatment with GnRH-a has little effect on ovarian protection in women with Hodgkin's disease.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2593773 | PMC |
http://dx.doi.org/10.1007/s10815-008-9276-4 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!